The DNA damage response (DDR) pathway is an essential mechanism used to maintain genomic integrity in all cells. Nearly all cancers have deficiencies in one or two DDR pathways, resulting in increased dependence on alternate, less accurate pathways.1,2 Poly ADP-ribose polymerase (PARP) inhibitors are oral agents developed to inhibit these compensatory pathways, resulting in “synthetic lethality,” or the death of the DDR defective cell. PARP inhibitors have thus far been shown to be effective in BRCA mutation-positive tumors, including ovarian, breast, and other cancers.3 While these oral agents offer patients increased flexibility, there also is the potential for incorrect administration, increased drug interactions and decreased adherence.Oncology pharmacists have extensive knowledge regarding pharmacokinetic, pharmacodynamic, efficacy and financial aspects of oral chemotherapy and are optimally positioned to play a vital role in the oral cancer therapy management of PARP inhibitors. Thus, it is vital that oncology pharmacists be up-to-date on the latest advances in PARP inhibition, including emerging indications and drug formulations, recognition and management of adverse events, appropriate therapy selection based on genetic testing results, and patient adherence strategies.


Attendees of this symposium will gain an appreciation of the latest clinical and scientific advances in targeting DDR, including updates on the current and emerging prospects of PARP inhibitors for ovarian, breast, and other cancers. Using a case-based approach, faculty will discuss therapeutic selection, genetic testing and counseling, patient adherence strategies, and the recognition and management of adverse events for patients receiving PARP inhibitors.


1van Gent DC, et al. Mol Biol Cell. 2016. 2O’Connor MJ, et al. Mol Cell. 2015. 3Cerrato A, et al. J Exp Clin Canc Res. 2016. 4Felton MA, et al. J Oncol Pharm Pract. 2016.



James Ford, MD

Professor of Medicine and Genetics
Director, Stanford Program for Clinical Cancer Genomics
Division of Oncology
Stanford University School of Medicine
Stanford, CA
View Full Bio

Jason Bergsbaken, PharmD, BCOP

Pharmacy Coordinator, Regional Oncology Services
University of Wisconsin Hospital and Clinics
Madison, WI
View Full Bio



In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This application-based activity is approved for 1.50 contact hours (0.150 CEUs) of continuing pharmacy education credit (UAN JA0007101-0000-18-002-L01-P).


Creative Educational Concepts, Inc. certifies this activity for 1.50 hours of participation.


Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from AstraZeneca.